Go Pro
→ Louis Navellier: My #1 AI stock for 2026 (name & ticker inside) (From InvestorPlace) (Ad)tc pixel Free KRRO Stock Alerts

Korro Bio (KRRO) Financials

Korro Bio logo
$14.56 +0.26 (+1.82%)
Closing price 07/10/2026 04:00 PM Eastern
Extended Trading
$14.55 -0.01 (-0.07%)
As of 07/10/2026 04:10 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.
Compare
Annual Income Statements for Korro Bio

Annual Income Statements for Korro Bio

This table shows Korro Bio's income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric 2017 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2017 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Net Income / (Loss) Attributable to Common Shareholders		 -20 -19 -20 -27 -85 -58 -81 -83 -117
Consolidated Net Income / (Loss)		 -20 -19 -19 -27 -85 -58 -81 -84 -117
Net Income / (Loss) Continuing Operations		 -20 -19 -19 -27 -85 -58 -81 -84 -117
Total Pre-Tax Income 		-20 -19 -19 -26 -85 -58 -81 -83 -117
Total Operating Income		 -16 -19 -21 -28 -84 -59 -85 -92 -122
Total Gross Profit		 0.00 0.00 29 37 14 0.00 0.00 2.27 6.39
Total Revenue		 0.00 0.00 29 37 14 0.00 0.00 2.27 6.39
Operating Revenue		 0.00 0.00 29 37 14 - 0.00 2.27 6.39
Total Cost of Revenue		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Operating Expenses		 16 19 50 65 98 59 85 94 128
Selling, General & Admin Expense		 4.34 7.06 15 27 37 17 27 31 28
Research & Development Expense		 12 12 19 37 61 42 57 64 66
Impairment Charge		 - - - - - - - 0.00 31
Restructuring Charge		 - - - - - - - 0.00 3.63
Total Other Income / (Expense), net		 -3.92 -0.38 1.93 1.07 -0.64 0.98 3.39 8.47 5.23
Other Income / (Expense), net		 - - 0.15 0.08 -0.27 0.98 3.39 8.47 5.23
Income Tax Expense		 - - 0.00 0.04 0.02 0.01 0.03 0.14 0.64
Basic Earnings per Share		 ($28.79) ($12.53) ($2.29) ($0.82) ($2.47) ($227.42) ($53.08) ($9.37) ($12.48)
Weighted Average Basic Shares Outstanding		 702.92K 1.53M 8.65M 32.25M 34.35M 255.18K 1.53M 8.92M 9.40M
Diluted Earnings per Share		 ($28.79) ($12.53) ($2.29) ($0.82) ($2.47) ($227.42) ($53.08) ($9.37) ($12.48)
Weighted Average Diluted Shares Outstanding		 702.92K 1.53M 8.65M 32.25M 34.35M 255.18K 1.53M 8.92M 9.40M
Weighted Average Basic & Diluted Shares Outstanding		 702.92K 1.53M 8.65M 32.25M 34.35M 35.08M 8.02M 9.39M 14.42M

Quarterly Income Statements for Korro Bio

This table shows Korro Bio's income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026
Period end date 9/30/2023 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026
Net Income / (Loss) Attributable to Common Shareholders		 -18 -25 -20 -22 -20 -22 -23 -26 -18 -50 -20
Consolidated Net Income / (Loss)		 -18 -25 -20 -22 -21 -21 -23 -26 -18 -50 -20
Net Income / (Loss) Continuing Operations		 -18 -25 -20 -22 -21 -21 -23 -26 -18 -50 -20
Total Pre-Tax Income 		-18 -25 -20 -22 -21 -21 -23 -26 -18 -49 -20
Total Operating Income		 -19 -27 -21 -24 -23 -23 -25 -27 -19 -50 -20
Total Gross Profit		 0.00 - 0.00 0.00 0.00 2.27 2.55 1.46 1.09 1.29 0.00
Total Revenue		 0.00 - 0.00 0.00 0.00 2.27 2.55 1.46 1.09 1.29 0.00
Operating Revenue		 - - 0.00 0.00 0.00 - 2.55 1.46 1.09 1.29 0.00
Total Cost of Revenue		 0.00 - 0.00 0.00 0.00 - 0.00 0.00 0.00 - 0.00
Total Operating Expenses		 19 27 21 24 23 25 28 29 20 52 20
Selling, General & Admin Expense		 5.14 11 7.88 6.99 7.33 8.35 7.83 7.63 6.51 6.19 7.49
Research & Development Expense		 14 15 14 17 16 17 20 21 14 11 13
Total Other Income / (Expense), net		 0.66 1.47 1.91 2.33 2.28 1.94 1.63 1.43 1.18 0.99 0.91
Other Income / (Expense), net		 0.66 1.47 1.91 2.33 2.28 1.94 1.63 1.43 1.18 0.99 0.91
Income Tax Expense		 0.00 - 0.02 0.03 -0.01 0.10 0.00 0.00 0.00 0.64 0.10
Basic Earnings per Share		 ($65.08) $148.03 ($2.44) ($2.43) ($2.26) ($2.24) ($2.49) ($2.74) ($1.92) ($5.33) ($1.69)
Weighted Average Basic Shares Outstanding		 284.16K 1.53M 8.02M 8.99M 9.30M 8.92M 9.38M 9.39M 9.39M 9.40M 11.60M
Diluted Earnings per Share		 ($65.08) $148.03 ($2.44) ($2.43) ($2.26) ($2.24) ($2.49) ($2.74) ($1.92) ($5.33) ($1.69)
Weighted Average Diluted Shares Outstanding		 284.16K 1.53M 8.02M 8.99M 9.30M 8.92M 9.38M 9.39M 9.39M 9.40M 11.60M
Weighted Average Basic & Diluted Shares Outstanding		 36.93M 8.02M 9.27M 9.30M 9.37M 9.39M 9.39M 9.39M 9.42M 14.42M 14.42M

Annual Cash Flow Statements for Korro Bio

This table details how cash moves in and out of Korro Bio's business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric 2017 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2017 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Net Change in Cash & Equivalents		 12 24 158 22 -141 -43 132 -114 -34
Net Cash From Operating Activities		 -15 -17 34 -45 -76 -54 -67 -60 -79
Net Cash From Continuing Operating Activities		 -15 -17 34 -45 -76 -54 -67 -60 -79
Net Income / (Loss) Continuing Operations		 -20 -19 -19 -27 -85 -58 -81 -84 -117
Consolidated Net Income / (Loss)		 -20 -19 -19 -27 -85 -58 -81 -84 -117
Depreciation Expense		 0.53 0.65 0.81 1.15 2.78 2.51 3.63 3.57 4.28
Amortization Expense		 - - - - - -0.15 -0.08 -1.78 -0.49
Non-Cash Adjustments To Reconcile Net Income		 4.82 0.67 3.50 10 23 2.65 6.06 8.13 39
Changes in Operating Assets and Liabilities, net		 0.28 0.82 49 -30 -17 -0.63 4.28 14 -4.43
Net Cash From Investing Activities		 -1.86 -0.44 -18 10 -66 11 11 -123 44
Net Cash From Continuing Investing Activities		 -1.86 -0.44 -18 10 -66 11 11 -123 44
Purchase of Property, Plant & Equipment		 -1.86 -0.44 -1.06 -6.67 -2.91 -5.14 -7.84 -18 -0.52
Purchase of Investments		 0.00 0.00 -283 -26 -92 -37 0.00 -146 -26
Sale and/or Maturity of Investments		 0.00 0.00 265 43 29 53 19 41 71
Net Cash From Financing Activities		 28 42 142 57 1.36 0.02 188 69 0.69
Net Cash From Continuing Financing Activities		 28 42 142 57 1.36 0.02 188 69 0.69
Repayment of Debt		 - - - - 0.00 -0.04 -0.00 0.00 0.00
Issuance of Preferred Equity		 28 33 62 - - 0.00 45 0.00 0.00
Issuance of Common Equity		 0.03 3.85 80 42 1.36 0.00 117 67 0.00
Other Financing Activities, net		 - - - - - 0.06 25 1.97 0.69
Effect of Exchange Rate Changes		 - - - - - - 0.00 -0.00 0.06
Cash Income Taxes Paid		 0.00 0.00 - - - 0.01 0.03 0.14 0.00

Quarterly Cash Flow Statements for Korro Bio

This table details how cash moves in and out of Korro Bio's business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026
Period end date 9/30/2023 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026
Net Change in Cash & Equivalents		 -13 122 -27 -49 -28 -9.33 8.50 -31 -9.46 -2.33 40
Net Cash From Operating Activities		 -12 -21 -22 -15 -16 -7.50 -24 -19 -17 -18 -16
Net Cash From Continuing Operating Activities		 -12 -21 -22 -15 -16 -7.50 -24 -19 -17 -18 -16
Net Income / (Loss) Continuing Operations		 -18 -25 -20 -22 -21 -21 -23 -26 -18 -50 -20
Consolidated Net Income / (Loss)		 -18 -25 -20 -22 -21 -21 -23 -26 -18 -50 -20
Depreciation Expense		 0.92 0.99 0.73 0.72 0.87 1.25 1.23 1.23 1.18 0.65 0.38
Amortization Expense		 -0.00 - 0.00 -0.17 -0.99 -0.62 -0.34 -0.08 -0.05 -0.02 0.00
Non-Cash Adjustments To Reconcile Net Income		 1.46 2.53 2.07 2.08 2.09 1.90 1.92 2.25 2.00 33 2.97
Changes in Operating Assets and Liabilities, net		 4.34 0.81 -5.13 4.61 2.94 11 -3.87 3.15 -2.25 -1.45 0.20
Net Cash From Investing Activities		 0.75 -1.66 -5.61 -102 -13 -2.77 33 -11 7.60 15 -32
Net Cash From Continuing Investing Activities		 0.75 -1.66 -5.61 -102 -13 -2.77 33 -11 7.60 15 -32
Purchase of Property, Plant & Equipment		 -0.25 -1.66 -5.61 -5.96 -4.88 -1.45 -0.12 -0.14 -0.18 -0.08 -0.02
Purchase of Investments		 - - 0.00 -96 -22 -28 0.00 -11 -15 - -45
Sale and/or Maturity of Investments		 1.00 - 0.00 - 14 27 33 0.00 23 15 13
Net Cash From Financing Activities		 -2.19 145 0.14 68 0.73 0.93 0.17 0.01 0.13 0.38 88
Net Cash From Continuing Financing Activities		 -2.19 145 0.14 68 0.73 0.93 0.17 0.01 0.13 0.38 88
Issuance of Common Equity		 - 117 - - - 0.00 0.00 - - - 88
Other Financing Activities, net		 0.22 25 0.14 0.17 0.73 0.93 0.17 0.01 0.13 0.38 0.02
Effect of Exchange Rate Changes		 - - 0.00 - - -0.01 0.00 -0.01 -0.00 0.08 -0.03
Cash Income Taxes Paid		 - - 0.02 0.03 - 0.09 0.00 0.00 - - 0.05

Annual Balance Sheets for Korro Bio

This table presents Korro Bio's assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Total Assets		 45 223 265 185 74 222 226 114
Total Current Assets		 43 221 225 135 57 173 132 82
Cash & Equivalents		 42 200 220 80 36 166 56 22
Short-Term Investments		 0.00 17 0.00 51 19 0.00 70 53
Accounts Receivable		 - - - - - 0.00 1.70 0.97
Prepaid Expenses		 0.75 4.00 4.72 4.04 1.23 3.02 3.74 6.25
Plant, Property, & Equipment, net		 1.51 1.76 7.29 5.52 9.87 16 28 8.16
Total Noncurrent Assets		 0.10 0.10 32 45 6.79 33 67 23
Long-Term Investments		 - - - 12 - 0.00 37 10
Other Noncurrent Operating Assets		 0.10 0.10 32 33 6.79 33 30 13
Total Liabilities & Shareholders' Equity		 45 223 265 185 74 222 226 114
Total Liabilities		 4.12 56 72 55 8.91 52 66 62
Total Current Liabilities		 3.77 53 27 11 8.70 19 15 12
Accounts Payable		 1.86 1.22 5.51 2.75 2.61 7.28 3.99 1.65
Accrued Expenses		 1.75 3.24 6.66 6.10 3.18 10 6.17 7.61
Current Deferred Revenue		 0.00 48 14 - - 0.00 3.51 0.00
Other Current Liabilities		 0.16 0.17 0.40 1.75 2.92 1.99 1.28 2.67
Total Noncurrent Liabilities		 0.35 3.08 46 43 0.21 32 51 50
Capital Lease Obligations		 - - - - 0.21 31 43 41
Noncurrent Deferred Revenue		 0.00 2.90 0.00 - - 0.00 5.91 7.84
Other Noncurrent Operating Liabilities		 - 0.00 31 29 0.00 1.05 1.47 1.48
Commitments & Contingencies		 - - - - 0.00 0.00 0.00 0.00
Total Equity & Noncontrolling Interests		 -48 167 192 131 -99 170 160 51
Total Preferred & Common Equity		 -48 167 192 131 -99 170 160 51
Preferred Stock		 - 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Common Equity		 -48 167 192 131 -99 170 160 51
Common Stock		 0.81 236 288 311 2.81 353 427 435
Retained Earnings		 -49 -69 -95 -180 -102 -183 -267 -384
Accumulated Other Comprehensive Income / (Loss)		 0.00 0.05 0.03 -0.06 -0.01 0.00 0.27 0.21

Quarterly Balance Sheets for Korro Bio

This table presents Korro Bio's assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric Q3 2023 Q1 2024 Q2 2024 Q3 2024 Q1 2025 Q2 2025 Q3 2025 Q1 2026
Period end date 9/30/2023 3/31/2024 6/30/2024 9/30/2024 3/31/2025 6/30/2025 9/30/2025 3/31/2026
Total Assets		 46 198 250 244 202 180 162 184
Total Current Assets		 43 146 164 153 121 103 98 120
Cash & Equivalents		 42 139 91 63 64 34 24 62
Short-Term Investments		 0.00 - 66 74 51 63 68 52
Accounts Receivable		 - - - 10 1.92 1.09 0.82 0.00
Prepaid Expenses		 0.42 3.31 4.43 4.02 4.36 5.18 4.93 6.19
Plant, Property, & Equipment, net		 0.54 21 25 29 27 25 24 7.81
Total Noncurrent Assets		 3.31 32 61 62 54 52 39 56
Long-Term Investments		 - - 30 32 24 23 10 43
Other Noncurrent Operating Assets		 3.31 32 31 30 30 29 29 13
Total Liabilities & Shareholders' Equity		 46 198 250 244 202 180 162 184
Total Liabilities		 9.61 47 52 64 63 65 63 64
Total Current Liabilities		 9.61 11 12 14 13 17 15 15
Accounts Payable		 0.34 4.66 5.69 5.95 4.18 5.16 2.30 1.96
Accrued Expenses		 7.85 5.16 6.18 5.46 3.65 5.66 5.86 9.85
Current Deferred Revenue		 - - - 2.20 2.75 3.93 3.33 0.18
Other Current Liabilities		 1.43 1.24 0.46 0.00 2.31 2.43 3.15 2.80
Total Noncurrent Liabilities		 0.00 36 39 50 50 48 48 49
Capital Lease Obligations		 0.00 35 38 42 43 42 42 40
Noncurrent Deferred Revenue		 - - - 7.80 6.05 4.50 4.83 7.66
Other Noncurrent Operating Liabilities		 0.00 0.89 1.18 0.72 1.44 1.44 1.53 1.46
Commitments & Contingencies		 - 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Equity & Noncontrolling Interests		 37 151 198 180 139 115 99 120
Total Preferred & Common Equity		 37 151 198 180 139 115 99 120
Preferred Stock		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Common Equity		 37 151 198 180 139 115 99 120
Common Stock		 340 354 422 424 429 431 433 523
Retained Earnings		 -304 -203 -224 -245 -290 -316 -334 -403
Accumulated Other Comprehensive Income / (Loss)		 0.01 - 0.02 0.57 0.26 0.18 0.21 0.01

Annual Metrics And Ratios for Korro Bio

This table displays calculated financial ratios and metrics derived from Korro Bio's official financial filings.

Metric 2017 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2017 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
DEI Shares Outstanding		 0.00 0.00 30,784,936.00 33,734,692.00 34,602,285.00 35,262,083.00 36,926,285.00 - 9,417,295.00
DEI Adjusted Shares Outstanding		 0.00 0.00 30,784,936.00 33,734,692.00 34,602,285.00 35,262,083.00 36,926,285.00 - 9,417,295.00
DEI Earnings Per Adjusted Shares Outstanding		 0.00 0.00 -0.64 -0.79 -2.45 -1.65 -2.20 - -12.46
Growth Metrics		 - - - - - - - - -
Revenue Growth		 0.00% 0.00% 0.00% 27.76% -61.96% -100.00% 0.00% 0.00% 181.46%
EBITDA Growth		 0.00% -15.94% -7.80% -33.51% -209.71% 31.73% -39.42% -5.23% -38.18%
EBIT Growth		 0.00% -16.18% -8.37% -33.80% -206.89% 31.18% -39.85% -2.83% -39.77%
NOPAT Growth		 0.00% -16.18% -9.14% -33.25% -205.01% 29.79% -43.28% -8.73% -32.58%
Net Income Growth		 0.00% 5.28% 2.20% -41.42% -219.44% 31.47% -39.87% -2.97% -40.30%
EPS Growth		 0.00% 56.48% 81.72% 64.19% -201.22% -9,107.29% 76.66% 82.35% -33.19%
Operating Cash Flow Growth		 0.00% -16.49% 300.99% -232.07% -68.32% 29.47% -25.42% 10.71% -30.77%
Free Cash Flow Firm Growth		 0.00% 0.00% 386.41% -265.79% -33.45% 37.27% -72.85% 9.38% 30.15%
Invested Capital Growth		 0.00% 0.00% -3,423.13% 74.21% 126.44% 170.45% 241.83% 30.01% -82.70%
Revenue Q/Q Growth		 0.00% 0.00% 0.00% 16.51% -41.43% 0.00% 0.00% 0.00% -13.28%
EBITDA Q/Q Growth		 0.00% 0.00% 0.00% -16.43% -15.20% 32.96% -67.85% 4.64% -33.50%
EBIT Q/Q Growth		 0.00% 0.00% 0.00% -16.43% -15.18% 32.41% -64.62% 4.93% -32.06%
NOPAT Q/Q Growth		 0.00% 0.00% 0.00% -15.95% -15.19% 31.53% -63.09% 4.02% -28.95%
Net Income Q/Q Growth		 0.00% 0.00% 0.00% -21.77% -15.35% 32.30% -63.79% 4.81% -32.62%
EPS Q/Q Growth		 0.00% 0.00% 0.00% -117.86% -14.35% 0.00% 0.00% -106.65% -32.91%
Operating Cash Flow Q/Q Growth		 0.00% 0.00% -42.24% 24.81% -4.18% 11.34% -17.62% 18.47% -14.93%
Free Cash Flow Firm Q/Q Growth		 0.00% 0.00% 0.00% 0.00% 2.95% 43.66% -1,175.67% 39.81% 4.01%
Invested Capital Q/Q Growth		 0.00% 0.00% 0.00% 47.85% 106.57% -63.12% 730.04% -19.18% -81.44%
Profitability Metrics		 - - - - - - - - -
Gross Margin		 0.00% 0.00% 100.00% 100.00% 100.00% 0.00% 0.00% 100.00% 100.00%
EBITDA Margin		 0.00% 0.00% -68.11% -71.18% -579.54% 0.00% 0.00% -3,595.64% -1,765.21%
Operating Margin		 0.00% 0.00% -71.42% -74.49% -597.32% 0.00% 0.00% -4,047.12% -1,906.37%
EBIT Margin		 0.00% 0.00% -70.92% -74.28% -599.26% 0.00% 0.00% -3,674.15% -1,824.52%
Profit (Net Income) Margin		 0.00% 0.00% -64.76% -71.68% -601.98% 0.00% 0.00% -3,680.36% -1,834.48%
Tax Burden Percent		 100.04% 99.22% 100.00% 100.13% 100.02% 100.02% 100.03% 100.17% 100.55%
Interest Burden Percent		 124.06% 101.98% 91.31% 96.38% 100.44% 100.00% 100.00% 100.00% 100.00%
Effective Tax Rate		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Invested Capital (ROIC)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% -178.08% -356.09%
ROIC Less NNEP Spread (ROIC-NNEP)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% -163.17% -317.10%
Return on Net Nonoperating Assets (RNNOA)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 127.48% 245.39%
Return on Equity (ROE)		 0.00% -47.42% -18.04% -14.73% -52.39% -54.86% -64.76% -50.61% -110.70%
Cash Return on Invested Capital (CROIC)		 0.00% 0.00% 0.00% 0.00% -2,209.23% -748.18% -400.93% -204.18% -215.09%
Operating Return on Assets (OROA)		 0.00% 0.00% -15.33% -11.26% -37.46% 0.00% 0.00% -37.26% -68.65%
Return on Assets (ROA)		 0.00% 0.00% -14.00% -10.87% -37.63% 0.00% 0.00% -37.32% -69.03%
Return on Common Equity (ROCE)		 0.00% 56.63% -10.34% -14.73% -52.39% -8.24% -18.31% -50.61% -110.70%
Return on Equity Simple (ROE_SIMPLE)		 0.00% 39.70% -11.20% -13.77% -64.73% 58.60% -47.77% -52.10% 0.00%
Net Operating Profit after Tax (NOPAT)		 -11 -13 -14 -19 -59 -41 -59 -64 -85
NOPAT Margin		 0.00% 0.00% -50.00% -52.14% -418.12% 0.00% 0.00% -2,832.98% -1,334.46%
Net Nonoperating Expense Percent (NNEP)		 0.00% -28.24% -3.30% -3.42% -15.55% -16.82% -20.94% -14.91% -38.99%
Return On Investment Capital (ROIC_SIMPLE)		 - - - - - - -29.42% -31.55% -92.46%
Cost of Revenue to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
SG&A Expenses to Revenue		 0.00% 0.00% 51.26% 73.33% 264.26% 0.00% 0.00% 1,345.00% 440.54%
R&D to Revenue		 0.00% 0.00% 64.89% 101.17% 433.06% 0.00% 0.00% 2,802.11% 1,025.89%
Operating Expenses to Revenue		 0.00% 0.00% 171.42% 174.49% 697.32% 0.00% 0.00% 4,147.12% 2,006.37%
Earnings before Interest and Taxes (EBIT)		 -16 -19 -21 -27 -84 -58 -81 -83 -117
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)		 -16 -18 -20 -26 -82 -56 -78 -82 -113
Valuation Ratios		 - - - - - - - - -
Price to Book Value (P/BV)		 0.00 0.00 3.22 6.18 1.36 0.00 10.42 2.22 1.47
Price to Tangible Book Value (P/TBV)		 0.00 0.00 3.22 6.18 1.36 0.00 10.42 2.22 1.47
Price to Revenue (P/Rev)		 0.00 0.00 18.64 32.16 12.62 0.00 0.00 157.05 11.80
Price to Earnings (P/E)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Dividend Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Enterprise Value to Invested Capital (EV/IC)		 0.00 0.00 0.00 0.00 14.74 28.28 51.93 5.80 4.40
Enterprise Value to Revenue (EV/Rev)		 0.00 0.00 11.14 26.61 3.56 0.00 0.00 104.39 4.86
Enterprise Value to EBITDA (EV/EBITDA)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to EBIT (EV/EBIT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to NOPAT (EV/NOPAT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Operating Cash Flow (EV/OCF)		 0.00 0.00 9.43 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Free Cash Flow (EV/FCFF)		 0.00 0.00 9.50 0.00 0.00 0.00 0.00 0.00 0.00
Leverage & Solvency		 - - - - - - - - -
Debt to Equity		 0.00 0.01 0.00 0.08 0.11 0.00 0.18 0.27 0.79
Long-Term Debt to Equity		 0.00 0.01 0.00 0.08 0.11 0.00 0.18 0.27 0.79
Financial Leverage		 0.00 -1.04 -1.25 -1.17 -1.03 -0.94 -0.84 -0.78 -0.77
Leverage Ratio		 0.00 1.10 1.29 1.36 1.39 1.22 1.18 1.36 1.60
Compound Leverage Factor		 0.00 1.12 1.18 1.31 1.40 1.22 1.18 1.36 1.60
Debt to Total Capital		 0.00% 0.86% 0.11% 7.23% 10.29% 0.26% 15.52% 21.33% 44.24%
Short-Term Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.57% 0.00% 0.00% 0.00% 0.00%
Long-Term Debt to Total Capital		 0.00% 0.86% 0.11% 7.23% 9.72% 0.26% 15.52% 21.33% 44.24%
Preferred Equity to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital		 0.00% 217.55% 0.00% 0.00% 0.00% 222.06% 0.00% 0.00% 0.00%
Common Equity to Total Capital		 0.00% -118.41% 99.89% 92.77% 89.71% -122.31% 84.48% 78.67% 55.76%
Debt to EBITDA		 0.00 -0.02 -0.01 -0.57 -0.18 0.00 -0.40 -0.53 -0.36
Net Debt to EBITDA		 0.00 2.29 11.01 7.80 1.56 1.00 1.78 1.46 0.39
Long-Term Debt to EBITDA		 0.00 -0.02 -0.01 -0.57 -0.17 0.00 -0.40 -0.53 -0.36
Debt to NOPAT		 0.00 -0.03 -0.01 -0.78 -0.26 -0.01 -0.53 -0.68 -0.48
Net Debt to NOPAT		 0.00 3.16 15.01 10.65 2.17 1.35 2.34 1.86 0.52
Long-Term Debt to NOPAT		 0.00 -0.03 -0.01 -0.78 -0.24 -0.01 -0.53 -0.68 -0.48
Altman Z-Score		 0.00 10.34 6.10 10.07 -0.03 5.40 18.99 1.01 -6.59
Noncontrolling Interest Sharing Ratio		 0.00% 219.43% 42.69% 0.00% 0.00% 84.97% 71.72% 0.00% 0.00%
Liquidity Ratios		 - - - - - - - - -
Current Ratio		 0.00 11.38 4.19 8.45 11.79 6.56 8.87 8.79 6.90
Quick Ratio		 0.00 11.18 4.12 8.27 11.44 6.35 8.53 8.54 6.38
Cash Flow Metrics		 - - - - - - - - -
Free Cash Flow to Firm (FCFF)		 0.00 -12 34 -56 -75 -47 -81 -74 -52
Operating Cash Flow to CapEx		 -784.43% -3,904.59% 3,215.79% -677.38% -2,610.12% -1,044.49% -858.64% -335.57% -15,166.22%
Free Cash Flow to Firm to Interest Expense		 0.00 -31.59 0.00 0.00 -98.26 0.00 0.00 0.00 0.00
Operating Cash Flow to Interest Expense		 -3.73 -45.40 0.00 0.00 -99.55 0.00 0.00 0.00 0.00
Operating Cash Flow Less CapEx to Interest Expense		 -4.20 -46.56 0.00 0.00 -103.37 0.00 0.00 0.00 0.00
Efficiency Ratios		 - - - - - - - - -
Asset Turnover		 0.00 0.00 0.22 0.15 0.06 0.00 0.00 0.01 0.04
Accounts Receivable Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 4.80
Inventory Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Fixed Asset Turnover		 0.00 0.00 17.69 8.17 2.20 0.00 0.00 0.10 0.36
Accounts Payable Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Sales Outstanding (DSO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 76.09
Days Inventory Outstanding (DIO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Payable Outstanding (DPO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Cash Conversion Cycle (CCC)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 76.09
Capital & Investment Metrics		 - - - - - - - - -
Invested Capital		 0.00 -1.41 -50 -13 3.40 9.19 31 41 7.07
Invested Capital Turnover		 0.00 0.00 -1.13 -1.18 -2.98 0.00 0.00 0.06 0.27
Increase / (Decrease) in Invested Capital		 0.00 -1.41 -48 37 16 5.79 22 9.43 -34
Enterprise Value (EV)		 0.00 131 322 984 50 260 1,631 237 31
Market Capitalization		 84 84 540 1,189 178 136 1,770 357 75
Book Value per Share		 $0.00 ($31.55) $5.44 $5.71 $3.78 ($2.81) $4.60 $17.12 $5.46
Tangible Book Value per Share		 $0.00 ($31.55) $5.44 $5.71 $3.78 ($2.81) $4.60 $17.12 $5.46
Total Capital		 0.00 41 168 207 146 81 201 204 92
Total Debt		 0.00 0.35 0.18 15 15 0.21 31 43 41
Total Long-Term Debt		 0.00 0.35 0.18 15 14 0.21 31 43 41
Net Debt		 0.00 -42 -217 -205 -127 -56 -138 -120 -44
Capital Expenditures (CapEx)		 1.86 0.44 1.06 6.67 2.91 5.14 7.84 18 0.52
Debt-free, Cash-free Net Working Capital (DFCFNWC)		 0.00 -3.03 -49 -22 -6.56 -7.47 -16 -9.52 -4.72
Debt-free Net Working Capital (DFNWC)		 0.00 39 169 198 124 48 153 117 70
Net Working Capital (NWC)		 0.00 39 169 198 123 48 153 117 70
Net Nonoperating Expense (NNE)		 8.82 5.91 4.27 7.23 26 17 22 19 32
Net Nonoperating Obligations (NNO)		 0.00 -42 -217 -205 -127 -72 -138 -120 -44
Total Depreciation and Amortization (D&A)		 0.53 0.65 0.81 1.15 2.78 2.37 3.55 1.78 3.79
Debt-free, Cash-free Net Working Capital to Revenue		 0.00% 0.00% -168.51% -59.24% -46.60% 0.00% 0.00% -419.33% -73.86%
Debt-free Net Working Capital to Revenue		 0.00% 0.00% 582.36% 536.53% 882.51% 0.00% 0.00% 5,133.07% 1,101.92%
Net Working Capital to Revenue		 0.00% 0.00% 582.36% 536.53% 876.59% 0.00% 0.00% 5,133.07% 1,101.92%
Earnings Adjustments		 - - - - - - - - -
Adjusted Basic Earnings per Share		 $0.00 $0.00 ($2.29) ($0.82) ($2.47) ($2.33) ($53.08) ($9.37) ($12.48)
Adjusted Weighted Average Basic Shares Outstanding		 0.00 0.00 30.95M 34.18M 34.98M 35.29M 1.53M 8.92M 9.40M
Adjusted Diluted Earnings per Share		 $0.00 $0.00 ($2.29) ($0.82) ($2.47) ($2.33) ($53.08) ($9.37) ($12.48)
Adjusted Weighted Average Diluted Shares Outstanding		 0.00 0.00 30.95M 34.18M 34.98M 35.29M 1.53M 8.92M 9.40M
Adjusted Basic & Diluted Earnings per Share		 $0.00 $0.00 ($2.29) ($0.82) ($2.47) ($2.33) $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding		 0.00 0.00 8.65M 32.25M 34.35M 35.08M 8.02M 9.39M 14.42M
Normalized Net Operating Profit after Tax (NOPAT)		 -11 -13 -14 -19 -59 -41 -59 -64 -61
Normalized NOPAT Margin		 0.00% 0.00% -50.00% -52.14% -418.12% 0.00% 0.00% -2,832.98% -956.50%
Pre Tax Income Margin		 0.00% 0.00% -64.76% -71.59% -601.87% 0.00% 0.00% -3,674.15% -1,824.52%
Debt Service Ratios		 - - - - - - - - -
EBIT to Interest Expense		 -4.16 -50.52 0.00 0.00 -110.35 0.00 0.00 0.00 0.00
NOPAT to Interest Expense		 -2.91 -35.36 0.00 0.00 -76.99 0.00 0.00 0.00 0.00
EBIT Less CapEx to Interest Expense		 -4.63 -51.68 0.00 0.00 -114.16 0.00 0.00 0.00 0.00
NOPAT Less CapEx to Interest Expense		 -3.38 -36.52 0.00 0.00 -80.81 0.00 0.00 0.00 0.00
Payout Ratios		 - - - - - - - - -
Dividend Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Augmented Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%

Quarterly Metrics And Ratios for Korro Bio

This table displays calculated financial ratios and metrics derived from Korro Bio's official financial filings.

Metric Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026
Period end date 9/30/2023 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026
DEI Shares Outstanding		 36,520,750.00 36,926,285.00 8,021,946.00 9,272,987.00 9,298,815.00 - 9,388,902.00 9,390,492.00 9,390,903.00 9,417,295.00 14,422,571.00
DEI Adjusted Shares Outstanding		 36,520,750.00 36,926,285.00 8,021,946.00 9,272,987.00 9,298,815.00 - 9,388,902.00 9,390,492.00 9,390,903.00 9,417,295.00 14,422,571.00
DEI Earnings Per Adjusted Shares Outstanding		 -0.51 -0.69 -2.44 -2.35 -2.20 - -2.49 -2.75 -1.92 -5.31 -1.38
Growth Metrics		 - - - - - - - - - - -
Revenue Growth		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% -43.11% -100.00%
EBITDA Growth		 7.40% -457.12% 0.27% -27.10% -20.24% 16.26% -19.60% -15.89% 19.89% -138.34% 14.91%
EBIT Growth		 5.93% -495.61% 0.33% -23.69% -13.61% 17.03% -19.69% -18.23% 14.03% -134.20% 16.49%
NOPAT Growth		 5.56% -425.11% -6.81% -31.06% -21.64% 14.32% -16.63% -12.75% 17.41% -118.73% 18.32%
Net Income Growth		 5.40% -511.02% 0.24% -23.67% -13.56% 16.62% -19.58% -18.07% 13.99% -136.06% 16.09%
EPS Growth		 -11,732.73% 0.00% 96.62% 96.19% 96.53% -101.51% -2.05% -12.76% 15.04% -137.95% 32.13%
Operating Cash Flow Growth		 0.21% -91.41% -11.18% 0.83% -36.72% 64.49% -11.70% -31.76% -6.74% -136.18% 34.26%
Free Cash Flow Firm Growth		 144.04% -2,300,303.50% -370.82% -438.41% -535.33% 37.74% 51.30% 84.20% 98.62% 94.13% 255.23%
Invested Capital Growth		 -120.01% 241.83% 78.46% 4,449.25% 1,113.58% 30.01% -1.93% -19.02% -24.68% -82.70% -93.78%
Revenue Q/Q Growth		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 12.29% -42.75% -25.34% 18.53% -100.00%
EBITDA Q/Q Growth		 -5.13% -39.07% 23.02% -12.93% 0.54% 3.15% -9.95% -9.42% 31.24% -188.14% 60.75%
EBIT Q/Q Growth		 -4.94% -37.50% 23.15% -11.55% 3.62% -0.42% -10.86% -10.19% 29.91% -173.55% 60.47%
NOPAT Q/Q Growth		 -4.02% -40.44% 20.23% -12.46% 3.45% 1.08% -8.59% -8.72% 29.28% -161.97% 59.45%
Net Income Q/Q Growth		 -4.78% -37.50% 23.08% -11.60% 3.79% -0.95% -10.32% -10.19% 29.91% -177.07% 60.78%
EPS Q/Q Growth		 -1.96% 327.46% -101.65% 0.41% 7.00% 0.89% -11.16% -10.04% 29.93% -177.60% 68.29%
Operating Cash Flow Q/Q Growth		 20.00% -79.30% -3.71% 33.34% -10.29% 53.43% -226.24% 21.36% 10.66% -3.04% 9.20%
Free Cash Flow Firm Q/Q Growth		 237.74% -348.79% 16.62% -88.44% -11.37% 64.42% 34.77% 38.88% 90.27% -51.50% 1,823.61%
Invested Capital Q/Q Growth		 -365.98% 730.04% 39.07% 6.52% 8.60% -19.18% 4.90% -12.04% 1.00% -81.44% -62.30%
Profitability Metrics		 - - - - - - - - - - -
Gross Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 100.00% 100.00% 100.00% 100.00% 100.00% 0.00%
EBITDA Margin		 0.00% 0.00% 0.00% 0.00% 0.00% -901.19% -882.43% -1,686.44% -1,553.12% -3,775.46% 0.00%
Operating Margin		 0.00% 0.00% 0.00% 0.00% 0.00% -1,014.53% -981.18% -1,863.15% -1,764.86% -3,900.62% 0.00%
EBIT Margin		 0.00% 0.00% 0.00% 0.00% 0.00% -928.93% -917.14% -1,765.00% -1,656.97% -3,823.99% 0.00%
Profit (Net Income) Margin		 0.00% 0.00% 0.00% 0.00% 0.00% -933.47% -917.14% -1,765.07% -1,656.97% -3,873.22% 0.00%
Tax Burden Percent		 100.00% 100.00% 100.09% 100.14% 99.96% 100.49% 100.00% 100.00% 100.00% 101.29% 100.49%
Interest Burden Percent		 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00%
Effective Tax Rate		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Invested Capital (ROIC)		 0.00% 0.00% 0.00% 0.00% 0.00% -44.64% -76.53% -194.53% -205.56% -728.60% 0.00%
ROIC Less NNEP Spread (ROIC-NNEP)		 0.00% 0.00% 0.00% 0.00% 0.00% -40.71% -70.77% -188.65% -200.72% -710.59% 0.00%
Return on Net Nonoperating Assets (RNNOA)		 0.00% 0.00% 0.00% 0.00% 0.00% 31.81% 49.67% 137.92% 136.91% 549.90% 0.00%
Return on Equity (ROE)		 -83.50% -64.76% -79.30% -70.07% -81.17% -12.84% -26.86% -56.61% -68.65% -178.70% 0.00%
Cash Return on Invested Capital (CROIC)		 0.00% -400.93% -232.77% -240.11% -242.51% -204.18% -152.52% -142.80% -121.16% -215.09% -184.19%
Operating Return on Assets (OROA)		 0.00% 0.00% 0.00% 0.00% 0.00% -9.42% -22.10% -51.56% -60.30% -143.89% 0.00%
Return on Assets (ROA)		 0.00% 0.00% 0.00% 0.00% 0.00% -9.47% -22.10% -51.56% -60.30% -145.74% 0.00%
Return on Common Equity (ROCE)		 -83.50% -18.31% -79.30% -70.07% -81.17% -12.84% -26.86% -56.61% -68.65% -178.70% 0.00%
Return on Equity Simple (ROE_SIMPLE)		 -134.90% 0.00% -53.60% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Net Operating Profit after Tax (NOPAT)		 -13 -19 -15 -17 -16 -16 -18 -19 -13 -35 -14
NOPAT Margin		 0.00% 0.00% 0.00% 0.00% 0.00% -710.17% -686.82% -1,304.21% -1,235.40% -2,730.43% 0.00%
Net Nonoperating Expense Percent (NNEP)		 -10.30% -6.29% -6.65% -4.99% -5.50% -3.93% -5.76% -5.88% -4.84% -18.01% -4.99%
Return On Investment Capital (ROIC_SIMPLE)		 - -9.36% -8.07% -7.15% -7.36% -7.91% -9.63% -12.10% -9.58% -38.24% -8.96%
Cost of Revenue to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
SG&A Expenses to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 367.64% 307.10% 522.67% 596.97% 479.10% 0.00%
R&D to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 746.90% 774.08% 1,440.48% 1,267.89% 850.23% 0.00%
Operating Expenses to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 1,114.53% 1,081.18% 1,963.15% 1,864.86% 4,000.62% 0.00%
Earnings before Interest and Taxes (EBIT)		 -18 -25 -20 -22 -21 -21 -23 -26 -18 -49 -20
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)		 -18 -24 -19 -21 -21 -20 -23 -25 -17 -49 -19
Valuation Ratios		 - - - - - - - - - - -
Price to Book Value (P/BV)		 0.37 10.42 4.77 1.59 1.73 2.22 1.18 1.02 4.54 1.47 1.36
Price to Tangible Book Value (P/TBV)		 0.37 10.42 4.77 1.59 1.73 2.22 1.18 1.02 4.54 1.47 1.36
Price to Revenue (P/Rev)		 0.00 0.00 0.00 0.00 0.00 157.05 33.91 18.67 61.01 11.80 42.49
Price to Earnings (P/E)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Dividend Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Enterprise Value to Invested Capital (EV/IC)		 0.00 51.93 14.06 3.49 3.59 5.80 1.57 1.06 10.21 4.40 17.38
Enterprise Value to Revenue (EV/Rev)		 0.00 0.00 0.00 0.00 0.00 104.39 13.97 6.35 52.74 4.86 12.05
Enterprise Value to EBITDA (EV/EBITDA)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to EBIT (EV/EBIT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to NOPAT (EV/NOPAT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Operating Cash Flow (EV/OCF)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Free Cash Flow (EV/FCFF)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Leverage & Solvency		 - - - - - - - - - - -
Debt to Equity		 0.00 0.18 0.23 0.19 0.23 0.27 0.31 0.37 0.42 0.79 0.34
Long-Term Debt to Equity		 0.00 0.18 0.23 0.19 0.23 0.27 0.31 0.37 0.42 0.79 0.34
Financial Leverage		 -0.83 -0.84 -0.67 -0.81 -0.79 -0.78 -0.70 -0.73 -0.68 -0.77 -0.82
Leverage Ratio		 1.54 1.18 1.46 1.35 1.34 1.36 1.38 1.37 1.45 1.60 1.49
Compound Leverage Factor		 1.54 1.18 1.46 1.35 1.34 1.36 1.38 1.37 1.45 1.60 1.49
Debt to Total Capital		 0.00% 15.52% 18.64% 16.10% 18.87% 21.33% 23.58% 26.83% 29.54% 44.24% 25.10%
Short-Term Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Long-Term Debt to Total Capital		 0.00% 15.52% 18.64% 16.10% 18.87% 21.33% 23.58% 26.83% 29.54% 44.24% 25.10%
Preferred Equity to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Common Equity to Total Capital		 100.00% 84.48% 81.36% 83.90% 81.13% 78.67% 76.42% 73.17% 70.46% 55.76% 74.90%
Debt to EBITDA		 0.00 -0.40 -0.45 -0.46 -0.49 -0.53 -0.50 -0.48 -0.49 -0.36 -0.37
Net Debt to EBITDA		 0.00 1.78 1.39 1.85 1.51 1.46 1.13 0.87 0.72 0.39 1.07
Long-Term Debt to EBITDA		 0.00 -0.40 -0.45 -0.46 -0.49 -0.53 -0.50 -0.48 -0.49 -0.36 -0.37
Debt to NOPAT		 0.00 -0.53 -0.58 -0.59 -0.62 -0.68 -0.64 -0.61 -0.63 -0.48 -0.49
Net Debt to NOPAT		 0.00 2.34 1.79 2.36 1.93 1.86 1.44 1.12 0.92 0.52 1.42
Long-Term Debt to NOPAT		 0.00 -0.53 -0.58 -0.59 -0.62 -0.68 -0.64 -0.61 -0.63 -0.48 -0.49
Altman Z-Score		 -8.79 19.81 8.35 2.84 1.91 1.92 -0.17 -1.24 1.72 -4.64 -1.19
Noncontrolling Interest Sharing Ratio		 0.00% 71.72% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Liquidity Ratios		 - - - - - - - - - - -
Current Ratio		 4.42 8.87 13.18 13.28 11.23 8.79 9.41 5.98 6.71 6.90 8.13
Quick Ratio		 4.34 8.53 12.56 12.77 10.80 8.54 9.07 5.67 6.37 6.38 7.71
Cash Flow Metrics		 - - - - - - - - - - -
Free Cash Flow to Firm (FCFF)		 16 -41 -34 -64 -72 -26 -17 -10 -0.99 -1.50 26
Operating Cash Flow to CapEx		 -4,785.37% -1,275.35% -390.14% -244.81% -329.95% -516.18% -20,547.90% -13,734.29% -9,816.57% -21,073.81% -76,542.86%
Free Cash Flow to Firm to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Operating Cash Flow to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Operating Cash Flow Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Efficiency Ratios		 - - - - - - - - - - -
Asset Turnover		 0.00 0.00 0.00 0.00 0.00 0.01 0.02 0.03 0.04 0.04 0.02
Accounts Receivable Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 1.36 4.80 0.00
Inventory Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Fixed Asset Turnover		 0.00 0.00 0.00 0.00 0.00 0.10 0.20 0.25 0.28 0.36 0.22
Accounts Payable Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Sales Outstanding (DSO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 267.89 76.09 0.00
Days Inventory Outstanding (DIO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Payable Outstanding (DPO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Cash Conversion Cycle (CCC)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 267.89 76.09 0.00
Capital & Investment Metrics		 - - - - - - - - - - -
Invested Capital		 -4.99 31 44 47 51 41 43 38 38 7.07 2.66
Invested Capital Turnover		 0.00 0.00 0.00 0.00 0.00 0.06 0.11 0.15 0.17 0.27 0.17
Increase / (Decrease) in Invested Capital		 -30 22 19 48 56 9.43 -0.85 -8.85 -12 -34 -40
Enterprise Value (EV)		 -28 1,631 614 163 182 237 67 40 389 31 46
Market Capitalization		 14 1,770 722 314 311 357 163 117 450 75 163
Book Value per Share		 $1.01 $4.60 $18.87 $21.36 $19.32 $17.12 $14.80 $12.26 $10.55 $5.46 $8.29
Tangible Book Value per Share		 $1.01 $4.60 $18.87 $21.36 $19.32 $17.12 $14.80 $12.26 $10.55 $5.46 $8.29
Total Capital		 37 201 186 236 221 204 182 157 141 92 160
Total Debt		 0.00 31 35 38 42 43 43 42 42 41 40
Total Long-Term Debt		 0.00 31 35 38 42 43 43 42 42 41 40
Net Debt		 -42 -138 -108 -152 -129 -120 -96 -77 -61 -44 -117
Capital Expenditures (CapEx)		 0.25 1.66 5.61 5.96 4.88 1.45 0.12 0.14 0.18 0.08 0.02
Debt-free, Cash-free Net Working Capital (DFCFNWC)		 -8.84 -16 -7.75 -7.90 0.41 -9.52 -6.60 -11 -8.89 -4.72 -8.59
Debt-free Net Working Capital (DFNWC)		 33 153 135 151 139 117 108 85 84 70 105
Net Working Capital (NWC)		 33 153 135 151 139 117 108 85 84 70 105
Net Nonoperating Expense (NNE)		 5.09 6.60 4.54 4.94 4.69 5.07 5.87 6.73 4.60 15 5.32
Net Nonoperating Obligations (NNO)		 -42 -138 -108 -152 -129 -120 -96 -77 -61 -44 -117
Total Depreciation and Amortization (D&A)		 0.92 0.99 0.73 0.55 -0.12 0.63 0.89 1.15 1.13 0.63 0.38
Debt-free, Cash-free Net Working Capital to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% -419.33% -136.88% -173.56% -120.62% -73.86% -223.69%
Debt-free Net Working Capital to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 5,133.07% 2,247.54% 1,360.63% 1,134.01% 1,101.92% 2,742.74%
Net Working Capital to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 5,133.07% 2,247.54% 1,360.63% 1,134.01% 1,101.92% 2,742.74%
Earnings Adjustments		 - - - - - - - - - - -
Adjusted Basic Earnings per Share		 ($0.31) $148.03 ($2.44) ($2.43) ($2.26) ($2.24) ($2.49) ($2.74) ($1.92) ($5.33) ($1.69)
Adjusted Weighted Average Basic Shares Outstanding		 36.92M 1.53M 8.02M 8.99M 9.30M 8.92M 9.38M 9.39M 9.39M 9.40M 11.60M
Adjusted Diluted Earnings per Share		 ($0.31) $148.03 ($2.44) ($2.43) ($2.26) ($2.24) ($2.49) ($2.74) ($1.92) ($5.33) ($1.69)
Adjusted Weighted Average Diluted Shares Outstanding		 36.92M 1.53M 8.02M 8.99M 9.30M 8.92M 9.38M 9.39M 9.39M 9.40M 11.60M
Adjusted Basic & Diluted Earnings per Share		 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding		 36.93M 8.02M 9.27M 9.30M 9.37M 9.39M 9.39M 9.39M 9.42M 14.42M 14.42M
Normalized Net Operating Profit after Tax (NOPAT)		 -13 -19 -15 -17 -16 -16 -18 -19 -13 -35 -14
Normalized NOPAT Margin		 0.00% 0.00% 0.00% 0.00% 0.00% -710.17% -686.82% -1,304.21% -1,235.40% -2,730.43% 0.00%
Pre Tax Income Margin		 0.00% 0.00% 0.00% 0.00% 0.00% -928.93% -917.14% -1,765.00% -1,656.97% -3,823.99% 0.00%
Debt Service Ratios		 - - - - - - - - - - -
EBIT to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
NOPAT to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
EBIT Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
NOPAT Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Payout Ratios		 - - - - - - - - - - -
Dividend Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Augmented Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%

Financials Breakdown Chart

Key Financial Trends

Korro Bio (NASDAQ: KRRO) is still a pre-commercial biotech story with a very strong cash position, but it is also burning a significant amount of cash and remains deeply unprofitable. The latest quarter shows a company that continues to fund research and development, with no revenue in Q1 2026 and operating losses that remain large relative to its size.

  • Cash and investments remain substantial. As of Q1 2026, Korro Bio held $61.7 million in cash and equivalents, $52.3 million in short-term investments, and $43.1 million in long-term investments.
  • Liquidity improved quarter over quarter. Total current assets rose to $120.2 million in Q1 2026 from $98.2 million in Q3 2025, helped by a larger cash and investment balance.
  • The company successfully raised capital. Q1 2026 included $88.2 million of cash from common equity issuance, which significantly boosted the balance sheet.
  • Deferred revenue and other liabilities suggest some ongoing business activity. Korro Bio reported $179,000 in current deferred revenue and $7.7 million in noncurrent deferred revenue in Q1 2026.
  • Revenue remains inconsistent and small. The company reported $0 revenue in Q1 2026 after posting $1.3 million in Q4 2025, $1.1 million in Q3 2025, and $1.5 million in Q2 2025.
  • Research spending remains high. Q1 2026 R&D expense was $13.0 million, only modestly below the $13.8 million spent in Q3 2025 and still the main driver of losses.
  • Balance sheet leverage is not debt-free. The company reported $40.1 million of capital lease obligations and total liabilities of $63.9 million in Q1 2026.
  • Equity remains positive but retained earnings are deeply negative. Total common equity was $119.6 million, but retained earnings stood at negative $403.5 million, reflecting years of cumulative losses.
  • Losses remain large. Q1 2026 net loss was $19.6 million, compared with a $50.0 million loss in Q4 2025, showing ongoing unprofitability.
  • Operating cash burn remains significant. Q1 2026 operating cash flow was negative $16.1 million, following negative $17.7 million in Q4 2025 and negative $17.2 million in Q3 2025.
  • Cash burn has been persistent across the last several quarters. Even with investment activity and financing, the company has repeatedly posted negative net change in cash from operations.

Bottom line: Korro Bio’s financial picture is typical of an early-stage biotech company: plenty of cash today, but no meaningful revenue and continuing heavy losses. The near-term investment case likely depends on clinical and pipeline progress rather than current fundamentals, and dilution risk remains a key factor after the recent equity raise.

07/11/26 10:49 PM ETAI Generated. May Contain Errors.

Korro Bio Financials - Frequently Asked Questions

According to the most recent income statement we have on file, Korro Bio's financial year ends in December. Their financial year 2025 ended on December 31, 2025.

Korro Bio's net income appears to be on an upward trend, with a most recent value of -$117.26 million in 2025, rising from -$20.24 million in 2017. The previous period was -$83.58 million in 2024. Find out what analysts predict for Korro Bio in the coming months.

Korro Bio's total operating income in 2025 was -$121.86 million, based on the following breakdown:
  • Total Gross Profit: $6.39 million
  • Total Operating Expenses: $128.25 million

Over the last 8 years, Korro Bio's total revenue changed from $0.00 in 2017 to $6.39 million in 2025, a change of 639,200,000.0%.

Korro Bio's total liabilities were at $62.07 million at the end of 2025, a 5.7% decrease from 2024, and a 1,405.7% increase since 2018.

In the past 7 years, Korro Bio's cash and equivalents has ranged from $21.82 million in 2025 to $220.34 million in 2020, and is currently $21.82 million as of their latest financial filing in 2025.

Over the last 8 years, Korro Bio's book value per share changed from 0.00 in 2017 to 5.46 in 2025, a change of 546.2%.


Related Companies

Financial statements for NASDAQ:KRRO last updated on 7/9/2026 by MarketBeat.com Staff. New filings and market data are monitored continuously.
From Our Partners
Trump's gold order: the announcement they won't put on the front page
On August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no deb...
Reagan Gold Group | Sponsoredtc pixel
The $15 Gold Fund That Pays Up to $1,152/Month
Gold is hitting record highs, but most investors are leaving income on the table. A $15 fund is quietly paying...
Investors Alley | Sponsoredtc pixel
Trump Takes Emergency Action - Plus Elon Musk's New Venture
Elon Musk has quietly launched a new venture - one that has nothing to do with rockets, EVs, or Neuralink. Tru...
Altimetry | Sponsoredtc pixel
Do NOT Buy SpaceX – Do This Instead
SpaceX just went public - and Whitney Tilson, Harvard MBA and 30-year Wall Street veteran, says buying in coul...
Stansberry Research | Sponsoredtc pixel
Your $29.97 book is free today
Why Some Traders Skip Stocks Entirely You don't need a big account to trade options. In fact, options ca...
Profits Run | Sponsoredtc pixel
SPCX Warning - and Worst News for Stocks in 50 Years
Goldman Sachs and Morgan Stanley are now predicting what could be the worst news for the U.S. stock market in ...
TradeSmith | Sponsoredtc pixel
CODE RED: AI Meltdown Imminent?
After correctly predicting the 2008 and 2020 stock market meltdowns, I believe this AI company is about to tri...
Paradigm Press | Sponsoredtc pixel
Better than SpaceX? Grab this ticker instead.
Larry Benedict generated $274 million for his clients by finding the trades most investors missed. Now he says...
Brownstone Research | Sponsoredtc pixel